Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 19 of 19 results for nintedanib cancer- non-small cell lung cancer

  1. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development Reference number: GID-TA11277 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA428

  3. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  4. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer

    News
    Last updated
    26 January 2024